# A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

> **NCT01076699** · PHASE2 · SUSPENDED · sponsor: **Revogenex, Inc.** · enrollment: 192 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** 0.075 mg RVX-100
- **DRUG:** 0.125 mg RVX-100
- **DRUG:** 0.250 mg RVX-100
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01076699
- **Lead sponsor:** Revogenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2010-03
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 192 (ESTIMATED)
- **Why stopped:** recruiting/enrolling participants has halted prematurely but potentially will resume Oct
- **Last updated:** 2010-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076699, "A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01076699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*